Assess Incidence and Prevalence of Brain Metastasis and Its impact on Clinical Outcomes among Anaplastic Lymphoma Kinase (ALK) Positive Metastatic Non-small Cell Lung Cancer Patients Receiving ALK Inhibitors as First-Line Treatment in the United States (ALK+ mNSCLC)

Study type

• Study topic:
  Disease /health condition

  Human medicinal product
• Study type:
  Non-interventional study
• Scope of the study:
  Feasibility analysis

Non-interventional study

• Non-interventional study design:
  Cohort

Study drug and medical condition

• Medicinal product name:
  XALKORI
• Study drug International non-proprietary name (INN) or common name:
  CRIZOTINIB
• Anatomical Therapeutic Chemical (ATC) code:
  (L01ED01) crizotinib

  crizotinib
• Medical condition to be studied:
  Non-small cell lung cancer metastatic
• Additional medical condition(s):
  Anaplastic Lymphoma Kinase (ALK) Positive Metastatic Non-small Cell Lung Cancer